Last reviewed · How we verify
RELEUKO (FILGRASTIM-AYOW)
RELEUKO (generic name: FILGRASTIM-AYOW) is a Leukocyte Growth Factor [EPC] drug developed by KASHIV BIOSCIENCES LLC. It is currently FDA-approved.
At a glance
| Generic name | FILGRASTIM-AYOW |
|---|---|
| Sponsor | KASHIV BIOSCIENCES LLC |
| Drug class | Leukocyte Growth Factor [EPC] |
| Therapeutic area | Other |
| Phase | FDA-approved |
Approved indications
Common side effects
- Diarrhea
- Constipation
- Vomiting
- Anemia
- Oral pain
- Asthenia
- Malaise
- Peripheral edema
- Hemoglobin decreased
- Decreased appetite
- Oropharyngeal pain
- Alopecia
Key clinical trials
- A Pilot Trial of Cisplatin/Etoposide/Radiotherapy Followed by Consolidation Docetaxel and the Addition of Bevacizumab (NSC-704865) in Three Cohorts of Patients With Inoperable Locally Advanced Stage I (Phase 2)
- Ruxolitinib in Combination With Chemotherapy for Untreated Nodal T-Follicular Helper (TFH) Cell Lymphomas (Phase 1)
- A Phase 2 Trial of Chemotherapy Followed by Response-Based Whole Ventricular &Amp; Spinal Canal Irradiation (WVSCI) for Patients With Localized Non-Germinomatous Central Nervous System Germ Cell Tumor (Phase 2)
- A Phase III Randomized Trial for the Treatment of Newly Diagnosed Supratentorial PNET and High Risk Medulloblastoma in Children < 36 Months Old With Intensive Induction Chemotherapy With Methotrexa (Phase 3)
- Treatment of Atypical Teratoid/Rhabdoid Tumors (AT/RT) of the Central Nervous System With Surgery, Intensive Chemotherapy, and 3-D Conformal Radiation (Phase 3)
- A Phase 1/2 Study of CPX-351 (NSC# 775341) Alone Followed by Fludarabine, Cytarabine, and G-CSF (FLAG) for Children With Relapsed Acute Myeloid Leukemia (AML) (Phase 1)
- A Randomized Phase 3 Trial of Nivolumab (NSC# 748726) in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma (Phase 3)
- A Pilot Study of Ibrutinib and R-da-EPOCH for Front Line Treatment of AIDS-Related Lymphomas (Phase 1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- RELEUKO CI brief — competitive landscape report
- RELEUKO updates RSS · CI watch RSS
- KASHIV BIOSCIENCES LLC portfolio CI
Frequently asked questions about RELEUKO
What is RELEUKO?
RELEUKO (FILGRASTIM-AYOW) is a Leukocyte Growth Factor [EPC] drug developed by KASHIV BIOSCIENCES LLC.
Who makes RELEUKO?
RELEUKO is developed and marketed by KASHIV BIOSCIENCES LLC (see full KASHIV BIOSCIENCES LLC pipeline at /company/kashiv-biosciences-llc).
What is the generic name of RELEUKO?
FILGRASTIM-AYOW is the generic (nonproprietary) name of RELEUKO.
What drug class is RELEUKO in?
RELEUKO belongs to the Leukocyte Growth Factor [EPC] class. See all Leukocyte Growth Factor [EPC] drugs at /class/leukocyte-growth-factor-epc.
What development phase is RELEUKO in?
RELEUKO is FDA-approved (marketed).
What are the side effects of RELEUKO?
Common side effects of RELEUKO include Diarrhea, Constipation, Vomiting, Anemia, Oral pain, Asthenia.
Related
- Drug class: All Leukocyte Growth Factor [EPC] drugs
- Manufacturer: KASHIV BIOSCIENCES LLC — full pipeline
- Therapeutic area: All drugs in Other